All Posts By

Blackhawk Growth

Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat Major Depressive Disorder

Vancouver, British Columbia – TheNewswire – January 17, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary MindBio Therapeutics Pty Ltd (“MindBio”) is developing a new microdosing formula using LSD (Lysergic Acid Diethylamide) to treat Major Depressive Disorder (“MDD”).     MindBio aims to develop psychedelic microdosing formulations…

Read More

Blackhawk’s TERP Wholesale LLC Receives State-Issued Micro-Business License Allowing for Retail Delivery

Vancouver, British Columbia – TheNewswire – January 12, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is pleased to announce that its wholly-owned subsidiary, TERP Wholesale, LLC (“TERP”) has received its California State-issued micro-business license. In addition to allowing TERP to operate as a non-storefront retail delivery dispensary, this license provides strategic opportunities to expand in additional verticals…

Read More

Blackhawk’s TERP Wholesale LLC Reports Unaudited $2,503,133 in Gross Revenue for Nine Months Ended September 30th, 2021

  Vancouver, British Columbia – TheNewswire – January 6, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is pleased to provide an update on the operations of its wholly owned subsidiary, TERP Wholesale, LLC (“TERP”). The acquisition of TERP was successfully completed on December 1, 2021.     For the nine months ended September 30, 2021, TERP reported…

Read More

Blackhawk’s MindBio Therapeutics to Develop Proprietary Drug Delivery Technology for Psychedelic Medicines

Vancouver, British Columbia – TheNewswire – January 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), is developing a proprietary technology and a new scientific method to objectively test the effectiveness and delivery of microdosing psychedelic medicines.   MindBio is currently…

Read More

Blackhawk Growth’s Digital Mind Technology Set to Pioneer Novel Treatment in Pain Management in Cancer Patients; Preparations for Phase 1 Clinical Trials Underway

  To help reduce opioid reliance, misuse and abuse  Improve mood and reduce risk of depression and related health disorders  Help cancer patients live better with illness    Vancouver, British Columbia – TheNewswire – December 20, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly-owned subsidiary, Digital Mind Technology Pty…

Read More

Blackhawk Growth Announces Plan to Spin-Out Psychedelic Subsidiaries and Proposes 1:1 Distribution Ratio

  Vancouver, British Columbia – TheNewswire – December 15, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) ( “Blackhawk”), is pleased to announce that it intends to undertake a spin-out transaction whereby the shares of its wholly owned subsidiaries MindBio Therapeutics Pty. Ltd. and Digital Mind Technology Pty Ltd. will form an independent company to focus solely on the psychedelics…

Read More

Blackhawk Growth Fully Funds Phase II Clinical Trials in Psychedelics and Begins Development of Digital Mental Health Treatments

  Vancouver, British Columbia – TheNewswire – December 13, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (“Blackhawk”), is pleased to provide an update on its clinical trials for both of its wholly-owned subsidiaries MindBio Therapeutics PTY Ltd. (“MindBio”) and Digital Mind Technology PTY Ltd. (“Digital Mind”).   MindBio Clinical Trial Update   MindBio is accelerating its clinical trial program…

Read More

Blackhawk Growth to Complete Strategic Investment of Digital Mind Technology; Fully Funds Phase 1 Clinical Trial for Digital Mind and Phase 2 Clinical Trial for MindBio Therapeutics

   Highlights: Complementary acquisition of digital wellness company with AUD$2.5M cash on hand  Digital Mind Technology has a fully funded Phase 1 Clinical Trial ongoing  Adds several new high profile and leading institutional psychedelic funds as Blackhawk shareholders  MindBio Therapeutics fully funded Phase 2 Clinical Trials  Blackhawk holding leading assets in legal psychedelic and mental health therapies     Vancouver, British…

Read More

Blackhawk Growth Completes Investment in California-Based Licensed Distribution Center – TERP Wholesale, LLC, Company Generated CAD$3,902,888 Revenue in 2020

Vancouver, British Columbia – TheNewswire – December 1, 2021 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (Frankfurt:0JJ) (CNSX:BLR.CN) is pleased to announce that it has signed a definitive purchase agreement for the acquisition of all the outstanding membership interests in TERP Wholesale, LLC (“TERP”). The acquisition was previously announced on April 15, 2021 in connection with the signing of a…

Read More

Blackhawk Growth Files Quarter Ended September 30, 2021 Financials and Reports Increase in Value of its Portfolio by 165% Quarter Over Quarter

  Vancouver, British Columbia – TheNewswire – November 29, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company”), is pleased to announce that the financial statements and MD&A for its first quarter ended September 30, 2021 have been filed on Sedar. Highlights for the quarter ended September 30, 2021: Blackhawk acquires MindBio Therapeutics Pyt Ltd., clinical stage drug…

Read More